Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Gut. 2023 Jan;72(1):54-65. doi: 10.1136/gutjnl-2022-327471. Epub 2022 May 17.
There are altered mucosal functions in irritable bowel syndrome with diarrhoea (IBS-D); ~30% of patients with IBS-D have abnormal bile acid (BA) metabolism (ABAM) and diarrhoea (summarised as BAD).
To compare biochemical parameters, gastrointestinal and colonic transit, rectal sensation and pathobiological mechanisms in IBS-D without ABAM and in BAD (serum 7C4>52 ng/mL).
In patients with Rome III criteria of IBS-D, we compared biochemical features, colonic transit, rectal sensation, deep genotype of five BA-related genes, ileal and colonic mucosal mRNA (differential expression (DE) analysis) and stool dysbiosis (including functional analysis of microbiome). Results in BAD were compared with IBS-D without ABAM.
Compared with 161 patients with IBS-D without ABAM, 44 patients with BAD had significantly faster colonic transit, lower microbial alpha diversity, different compositional profile (beta diversity) and higher Firmicutes to Bacteroidetes ratio with evidence of decreased expression of bile acid thiol ligase (involved in transformation of primary to secondary BAs) and decreased sulfatases. In BAD (compared with IBS-D without ABAM), terminal ileal biopsies showed downregulation of (a BA transporter), and ascending colon biopsies showed upregulation in barrier-weakening genes (), serine protease inhibitors, immune activation, cellular differentiation and a cellular transporter (; BA binding). No DE of genes was documented in descending colon biopsies. The two groups had similar rectal sensation.
Though sharing clinical symptoms with IBS-D, BAD is associated with biological differences and mechanisms that have potential to enhance diagnosis and treatment targeting barrier dysfunction, inflammatory and microbial changes.
腹泻型肠易激综合征(IBS-D)存在黏膜功能改变;~30%的 IBS-D 患者存在异常胆汁酸(BA)代谢(ABAM)和腹泻(总结为 BAD)。
比较 IBS-D 中无 ABAM 和 BAD(血清 7C4>52ng/ml)患者的生化参数、胃肠道和结肠转运、直肠感觉和病理生物学机制。
在符合罗马 III 标准的 IBS-D 患者中,我们比较了生化特征、结肠转运、直肠感觉、五个与 BA 相关基因的深层基因型、回肠和结肠黏膜 mRNA(差异表达(DE)分析)和粪便微生物失调(包括微生物组功能分析)。将 BAD 的结果与 IBS-D 中无 ABAM 进行比较。
与 161 例无 ABAM 的 IBS-D 患者相比,44 例 BAD 患者的结肠转运明显更快,微生物 α多样性更低,组成谱(β多样性)不同,厚壁菌门与拟杆菌门的比例更高,胆汁酸硫转移酶(参与初级 BA 向次级 BA 的转化)和磺基转移酶表达下降。在 BAD(与 IBS-D 无 ABAM 相比)中,回肠末端活检显示 BA 转运蛋白下调,升结肠活检显示屏障减弱基因上调(、丝氨酸蛋白酶抑制剂、免疫激活、细胞分化和细胞转运蛋白;BA 结合)。降结肠活检未发现基因差异表达。两组直肠感觉相似。
尽管与 IBS-D 具有相同的临床症状,但 BAD 与生物学差异和机制相关,这些差异和机制有可能增强针对屏障功能障碍、炎症和微生物变化的诊断和治疗。